EGFR and non-small cell lung carcinoma: Furthermore, the LUX-Lung 7 study revealed a significantly improved PFS (11.0 months versus 10.9 months; HR: 0.73; 95% CI, 0.57–0.95; p = 0.017) and time-to-treatment failure (13.7 months versus 11.5 months; HR: 0.73; 95% CI, 0.58–0.92; p = 0.0073) in patients with EGFR-mutated NSCLC treated with afatinib as compared to gefinitib.